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Objectives: The alterations of the coagulation-fibrinolytic profile immediately and
up to few days after cardiac surgery have been widely documented. However, less
information is available on whether these alterations persist for prolonged periods of
time after the operation. In this study we have evaluated the coagulation-fibrinolytic
profile of patients who underwent coronary artery surgery with cardiopulmonary
bypass during a 2-month follow-up period.
Methods: Twenty-six patients (age range, 50-75 years) were studied. Blood samples
were collected before the intervention and at different time points postoperatively up
to 2 months after the operation. Measurement of selected coagulation-fibrinolytic
variables was carried out in plasma from 16 patients. Evaluation of tissue factor
activity determined as procoagulant activity was performed in peripheral blood
mononuclear leukocytes obtained from 10 patients.
Results: Antigenic levels of clottable fibrinogen, prothrombin fragment F1.2, D-
dimer, and thrombin-antithrombin complex were significantly increased during the
first week after the intervention compared with preoperative values. Prothrombin
fragment F1.2 levels returned to normal within 15 days, fibrinogen levels normal-
ized within 30 days, and thrombin-antithrombin complex levels normalized at 45
days, whereas D-dimer values were still significantly higher 60 days postoperatively
respective to baseline values. There was a trend toward an increased procoagulant
activity from peripheral blood mononuclear leukocytes 4 days after the operation,
whereas no changes of factor VII measured either as antigen or in its coagulant and
activated forms were recorded throughout the study.
Conclusions: A marked activation of the coagulation-fibrinolytic system occurs after
cardiopulmonary bypass and lasts for at least 2 months thereafter. This finding
suggests that these alterations might account for the increased thrombotic risk of
these patients during the postoperative period.
Cardiac surgery with cardiopulmonary bypass (CPB) can alter nor-mal hemostatic balance and predispose patients either to immediaterisk of excessive bleeding or to later thrombotic complications,such as ischemic events or early graft occlusion.1,2 Moreover,activation of both the fibrinolytic and inflammatory pathways cancontribute to the so-called postpump syndrome, which is charac-
terized by an impairment of myocardial, cerebral, pulmonary, and renal function.3
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Early activation of coagulation, as shown by the in-
creased levels of prothrombin fragment F1.2 and thrombin-
antithrombin complex (TAT), has been documented in pa-
tients who underwent CPB during cardiac surgery.4-6
Activation of the fibrinolytic system follows. Indeed, in-
creased levels of D-dimer (XDP)7 and plasmin-antiplasmin
complex4 have been reported as a consequence of the acti-
vation of the coagulation system.
Activation of coagulation recognizes multiple pathways
that are related to various aspects of the intervention, such
as surgical trauma, interaction of blood with extensive non-
endothelial surfaces of the bypass circuit, and retransfusion
of pericardial blood.6,8 More recently, tissue factor (TF)
expressed by monocytes during and immediately after the
procedure has been reported to play a pivotal role in CPB-
induced coagulopathy.6,9 The end point of both intrinsic and
extrinsic coagulation pathways is indeed the generation of
thrombin, the prominent enzyme in the activation of hemo-
stasis.
The behavior of hemostatic variables immediately after
and in the time frame that spans from a few hours to 2 to 3
days after cardiac surgery with CPB is widely documented.8
On the contrary, less information is available about the
behavior of these variables in a longer follow-up period.
The lack of information is due to the fact that patients with
uncomplicated procedures are usually discharged from the
hospital 4 to 8 days after the operation, making it difficult to
recall them over time.
Previous studies from our group and others10-12 have
reported increased thrombin generation and alteration of
fibrinolytic activity in patients undergoing CPB that lasted
up to 8 to 30 days after the intervention and that were not
prevented by the administration of aprotinin during the
procedure.10
On this basis, it might be hypothesized that cardiac
surgery with CPB activation of the coagulation-fibrinolytic
pathways occurs not only during the operation but also later.
The goal of the present study was therefore to assess
whether alterations of the coagulation persist for longer
follow-up periods. Moreover, the contribution of TF from
mononuclear leukocytes in the occurrence of activation of
coagulation within the first week after the intervention has
been investigated.
Patients and Methods
Patients
Twenty-six patients were consecutively enrolled among those un-
dergoing CPB for elective coronary artery bypass graft surgery,
according to the American Heart Association/American College of
Cardiology guidelines.13 Preoperative ejection fraction was greater
than 30%, and left ventricular end-diastolic pressure was less than
20 mm Hg. In order to avoid excessive blood sampling from the
same subject, coagulation/fibrinolytic variables were measured in
16 patients whereas blood from 10 patients was processed for
peripheral blood mononuclear leukocyte (PBML) isolation. All
patients provided informed consent to participate in this study that
was approved by the Ethical Committee of Centro Cardiologico
Monzino IRCCS. None of the patients had renal or liver dysfunc-
tion or were taking drugs affecting coagulation-fibrinolytic vari-
ables.
Surgical Procedure
All patients underwent intervention by the same surgical team. On
the morning of the operation, patients received their usual dose of
antianginal drugs, with 2 to 5 mg of morphine and 1 mg of atropine
as premedication. Anesthesia was induced by the administration of
sodium thiopental (3 mg/kg), fentanyl (0.75 g/kg), succinylcho-
line (1 mg/kg), diazepam (10 mg), and pancuronium bromide (0.1
mg/kg). After endotracheal intubation, patients were ventilated to
normocapnia with an oxygen and air mixture. Boluses of fentanyl
(with or without droperidol), diazepam, and pancuronium bromide
were given when necessary. Cefuroxime (2 g) was given intrave-
nously for infection prophylaxis. A radial artery catheter and a
flow-directed pulmonary artery catheter (Swan-Ganz, Baxter/
American Edwards Laboratories) were inserted for hemodynamic
measurements. The extracorporeal circuit consisted of a roller
pump, hollow-fiber oxygenator with integrated heat exchanger,
arterial filter, open cardiotomy reservoir, and polyvinyl tubing
system. The extracorporeal circuit was primed with 1500 mL of
crystalloid solution and 5000 IU of bovine lung heparin. After
systemic heparinization (300 IU/kg bovine lung heparin), CPB was
initiated by the placement of cannulas in the ascending aorta and
right atrium (2-stage venous cannula). Activated clotting time was
kept at 440 seconds or greater with additional heparin. The non-
pulsatile flow rate was maintained at 2.4 Lmin1m2 during
the cooling and rewarming phases and at 2.0 Lmin1m2
during stable hypothermia. Before and after CPB, blood from
mediastinum was collected with a cell-saver device, washed, and
returned to the patient, whereas during CPB, mediastinal blood
was returned directly to the extracorporeal circuit. Mean arterial
pressure was kept at 50 to 90 mm Hg. Patients were cooled to 29°C
to 31°C and received a first dose (1000 mL) of cool (4°C antegrade
and retrograde high-potassium crystalloid cardioplegia (St Thomas
Hospital II Cardioplegic Solution, SALF) just after aortic cross-
clamping. This maneuver was repeated (250 mL retrogradely)
every 20 minutes of aortic crossclamp time. Disturbances in the
acid-base balance were appropriately treated, and acid-base equi-
librium was maintained by using the alpha-stat method. The he-
matocrit level was maintained within 18% to 25% throughout the
procedure.
After termination of the intervention, heparin was antagonized
with protamine sulfate at a 1:1 ratio (3 mg/kg). None of the
patients required inotropic support for weaning from CPB. After
the operation, patients were admitted to the intensive care unit
(ICU) and treated according to a standardized protocol. Mean
arterial blood pressure was kept at 70 to 90 mm Hg, heart rate at
70 to 90 beats/min, and cardiac index at greater than 2.0
Lmin1m2. Patients were ventilated to normocapnia, and an
arterial oxygen tension of 80 mm Hg with continuous positive-
pressure ventilation and positive end-expiratory pressure of 5 cm
H2O was maintained until extubation, according to the ICU regi-
men. Basic fluid administration consisted of 0.9% NaCl and poly-
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gelatine. Packed erythrocytes were infused when the hematocrit
level was less than 18% during CPB and less than 24% in the ICU.
When the cardiorespiratory condition had stabilized, patients were
transported to the ward for further recovery. In the postoperative
period, patients received subcutaneous heparin (5000 IU twice
daily), starting from 24 hours to 72 hours after CPB, followed by
aspirin (325 mg/day), which was usually given within the first and
second days after the intervention.
Follow-up
All the patients were hospitalized until the eighth postoperative
day. Sixteen of them had periodic follow-up visits (physical ex-
amination, electrocardiography, and blood collection for coagula-
tion-fibrinolytic variables) at the 15th postoperative day and every
15 days on completion of the study protocol at the 60th postop-
erative day.
Blood Sampling
Blood collection was performed from a peripheral vein through a
19-gauge needle in plastic tubes (0.13 mol/L sodium citrate or 15
U/mL heparin as an anticoagulant, see below) during the morning.
Blood for measurement of coagulation-fibrinolytic variables was
collected at the following time points: the day before the operation
(1) and the 4th (4), 8th (8), 15th (15), 30th (30), 45th
(45), and 60th (60) postoperative day. Blood for mononuclear
leukocyte isolation was collected the day before the operation
(1) and at the fourth (4) and eighth (8) postoperative day.
Laboratory Methods
For selected coagulation-fibrinolytic variable measurements,
plasma was prepared by means of centrifugation at 1500g for 20
minutes at 4°C from blood collected in 0.13 mol/L sodium citrate
(1:10 vol/vol) within 1 hour after venipuncture. Centrifugation was
carried out at room temperature for factor VII determination.
Plasma was divided into aliquots and frozen at 80°C until assay.
Fibrinogen levels were measured according to the method of
Clauss14 (Dade-Thrombin, Dade Diagnostics) with a coagulometer
(Schnitger Gross).
TAT, XDP, and factor VII antigen levels were determined by
using ELISA with commercially available kits, according to the
manufacturers’ recommendations (Enzygnost TAT, Dade Behring;
Dimer-test Gold Stripwell EIA kit, Instrumentation Laboratory;
and Asserachrom VII:ag, Stago Boehringer). Prothrombin frag-
ment F1.2 was assayed in heparinized plasma by using a commer-
cially available ELISA kit (Enzygnost F1.2, Dade Behring).
Plasma factor VII coagulant was assessed by using a 1-stage
clotting time assay with a coagulometer, with factor VII–deficient
plasma and human tissue thromboplastin as reagents (Instrumen-
tation Laboratory). Plasma factor VII activity was measured by
using a 1-stage clotting assay with a soluble mutant recombinant
TF (kind gift from J. H. Morrissey, University of Illinois) that
possesses cofactor activity for factor VII activity but fails to
support activation of factor VII.15 Clotting times were converted to
factor VII activity concentration (in nanograms per milliliter) by
means of comparison with a standard curve of purified recombi-
nant factor VII activity (National Institute of Biological Standards
and Control, United Kingdom, code 89/688). Coagulation-fibrino-
lytic data were normalized for hematocrit values.
Blood Sampling for PBML Isolation
Blood was drawn in sterile tubes containing heparin (10 U/mL)
and divided into 2 aliquots under sterile conditions, according to
the method of Osterud and Bjorklid.16 Saline solution or 2 ng/mL
bacterial lipopolysaccharide (LPS; Sigma) was added, and samples
were incubated at 37°C. Reaction was stopped after 2 hours by
adding ethylenediamine tetra-acetic acid (2%, pH 7.4). Platelet-
rich plasma was separated (2300 rpm for 4 minutes) and replaced
with culture medium RPMI (BioWhittaker Italia) containing so-
dium citrate. PBMLs were obtained by means of sedimentation on
Ficoll-Paque (Pharmacia) density gradient. Cells were washed,
resuspended in PBS, and diluted to 2  106/mL. Aliquots (100
L) of cell suspensions were subjected to repeated cycles of
freezing and thawing and used to assess procoagulant activity.
Assay of Procoagulant Activity
Procoagulant activity was measured on cell lysates by using the
plasma recalcification time assay. In brief, citrated plasma (100
L) was incubated with cell lysate (100 L), and 25 mol/L CaCl2
was added to initiate the reaction. Clotting times were converted
into arbitrary units by using reference curves determined with a
standard human placental thromboplastin preparation (Thromborel
Behring). The logarithm of the clotting times was related to the
logarithm of the procoagulant activity. Experiments performed
with factor VII–deficient plasma verified that the procoagulant
activity measured was TF activity. Data are therefore expressed as
units of TF activity per milliliter, and the TF activity ratio of
LPS-stimulated/LPS-unstimulated cells is reported.
Statistical Analysis
Clinical data of patients are reported as means  1 SD or as
percentages. Trends by time in prothrombin fragment F1.2, TAT,
fibrinogen, XDP, factor VII (as antigen or in its coagulant and
activated forms), and TF activity were studied by using a repeated
measurements analysis, taking into account the correlation among
the measurements at the different time periods. A variance com-
ponent correlation structure was used, and there was no evidence
that a more complex structure was needed. Contrasts were calcu-
lated to estimate the mean change of the different variables from
baseline. The normality assumptions were checked by using nor-
mal plots, and logarithm transformation was used to achieve nor-
mality for prothrombin fragment F1.2, TAT, and XDP. One sub-
ject was excluded from the analysis because of TAT and
prothrombin fragment F1.2 preoperative values exceeding 2 SDs.
Fractional polynomials were fitted to find suitable models for
the curved relationship between the different variables and time.17
In the graphs the predicted values from these models, as well as the
observed values for each subject by time, are plotted. All calcu-
lations were performed by using PROC MIXED and PROC GLM
in SAS software (SAS for Windows version 6.11, SAS Institute
Inc).
Results
Clinical Results
Clinical variables of the patients are reported in Table 1.
None of the patients underwent re-exploration for bleeding,
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and the postoperative course was uneventful and uncompli-
cated for all patients.
Coagulation-fibrinolytic Variables
Analysis of variance for repeated measures showed a sig-
nificant time effect for the variables prothrombin fragment
F1.2 (P  .0004), TAT (P  .0001), fibrinogen (P 
.0001), and XDP (P  .0001) and a trend toward a signif-
icant effect of time for TF activity (P  .06) expressed as
the ratio of LPS-stimulated/LPS-unstimulated activity. Fac-
tor VII as antigen and in its coagulant and activated forms
did not show significant variations over time (P  .1).
Prothrombin Fragment F1.2
Prothrombin fragment F1.2 levels increased significantly
from baseline (0.35  0.216 nmol/L) at the fourth and
eighth day postoperatively. The increase from baseline val-
ues, as estimated from percentage changes on the least-
squared means obtained from repeated measurements anal-
ysis, was 95.3% (95% confidence interval [CI], 38.5-175.5)
and 57.4% (95% CI, 12.2-120.7) at the fourth and eighth
day, respectively. Thereafter, these levels decreased, with
the estimated percentage change being 27.8% greater than
the baseline value 15 days after the intervention, with a
complete return to baseline values occurring at the 45th
postoperative day (Figure 1).
Thrombin-antithrombin complex
TAT levels increased from the baseline point (3.8  2.19
ng/mL) starting the fourth day after the operation and
reached its peak 15 days after the intervention, with a
percentage change estimated on the least-squared means
equal to 204.1% (95% CI, 95.1-374.1; Figure 2); TAT
levels remained significantly higher than baseline values up
to 30 days after the intervention (96.7%; 95% CI, 27.1-
204.4). A return to preoperative levels was detected at the
45th postoperative day.
Fibrinogen
Fibrinogen levels markedly increased from baseline (359 
88 mg/dL) at the fourth postoperative day (103.0%; 95%
CI, 73.8-137.1), remained significantly increased up to the
15th day (52.7%; 95% CI, 31.1-77.9), and returned to
preoperative levels within the 45th postoperative day (Fig-
ure 3).
XDP
XDP levels markedly and progressively increased from
baseline (0.044  0.083 g/mL) up to the 15th day after
CPB (9979.3%; 95% CI, 3291.6-29853.9). Then the lev-
els decreased, although remaining significantly higher re-
spective to baseline values even at the 60th day (418.8%;
95% CI, 74.6-1441.9; Figure 4).
Factor VII
No changes of factor VII activity and antigen and the
activated factor VII were detected throughout the postoper-
ative period (not shown).
TF Activity
Before the operation, freshly isolated PBMLs expressed
1.44  0.84 U/mL TF activity, and this increased to 5.01 
5.8 U/mL on exposure to 2 ng/mL LPS. TF activity in
unstimulated cells did not change postoperatively, whereas
it increased up to 8.05  6.9 U/mL at the fourth postoper-
ative day. TF activity expressed as the ratio of LPS-stimu-
lated/LPS-unstimulated PBMLs showed a trend (P  .06)
toward a significant increase at the fourth postoperative day
respective to preoperative values (Figure 5).
Discussion
Previous studies have shown that the early period after CPB
procedures is the period of highest risk for thrombotic
complications. The highest rate of bypass occlusions occurs
within the first months after CPB. During this period of
time, the percentage of patients who experience occlusion of
at least one graft is between 3% and 12% after 1 month,18
and this value can increase further 3 months after the
operation.19 In addition to the problem of graft occlusions,
other complications on a thrombotic basis can frequently
occur. The incidence rates reported for perioperative stroke
are usually from 2% to 3%,20 reaching 5% in some re-
ports.21 The majority of strokes occur, however, in a time
frame up to 10 days after surgical intervention, after awak-
ening from surgical intervention, or after an uneventful
neurologic recovery.21 This observation suggests that fac-
tors other than those related to the complexity of the inter-
vention might contribute to the occurrence of thrombotic
events.
Our results indicate that alterations of the coagulation-
fibrinolytic profile, which are markedly evident within 4 to
TABLE 1. Clinical variables of the patient population (n 
26)
Age (y) 59 5
BSA (m2) 1.88 0.19
Male sex 24 (92%)
Previous MI 15 (60%)
Stable angina 26 (100%)
Angiographic EF 56.9 7.9
Distal anastomoses 3.4 0.6
LITA use 26 (100%)
CPB time (min) 84 17
Xclamp time (min) 64 10
24-h bleeding (mL) 662 352
Re-exploration for bleeding 0
BSA, Body surface area; EF, ejection fraction; LITA, left internal thoracic
artery; MI, myocardial infarction; Xclamp, aortic crossclamp.
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8 days from the intervention, persist for at least 2 months of
the follow-up period. In more detail, fibrinogen levels were
significantly higher at the 15th postoperative day, and TAT
and XDP levels remained higher at the 30th and 60th
postoperative days, respectively. This latter finding suggests
that 2 months after the operation, the generation of plasmin
still persists, both as a consequence of ongoing removal of
hemostatic plugs and formation of uncovered intravascular
fibrin deposition. D-dimer is in fact recognized as an indi-
cator of fibrin formation in vivo.22 Moreover, as suggested
by others,23 increased levels of XDP might result from a
remodeling of clot in the operative site.
Up to now, only one study has evaluated the hemostatic-
prothrombotic profile after CPB during a relative long-term
follow-up (3 months).12 In this study TAT and fibrinogen
levels that were found to be significantly increased at the
Figure 1. Plasma levels of prothrombin fragment F1.2 preoperatively and up to the 60th postoperative day. Small
open circles represent observed values, and large filled circles represent fitted values from the statistical model.
Figure 2. Plasma levels of TAT preoperatively and up to the 60th postoperative day. Small open circles represent
observed values, and large filled circles represent fitted values from the statistical model.
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eighth day normalized after 3 months. Results from our
study document that thrombin generation is still increased 2
months after the operation.
A trend toward increase of TF activity by PBMLs was
detected 4 days postoperatively. This increase, regardless of
a large interindividual variability, indicates that monocyte
activation in terms of TF activity likely persists for at least
some days after the operation.
The extracorporeal circuit has been previously shown to
be critical in terms of monocyte activation. Indeed, Barstad
and colleagues9 showed an increase of TF in adherent
monocytes retrieved from the oxygenators immediately af-
ter bypass arrest that was reduced when heparin-coated
circuits and systemic heparinization were adopted. More-
over, as far as PBMLs are considered, alterations of the
extrinsic pathway of coagulation have been documented
during and soon after cardiac surgery performed with the
use of CPB.5,24 Ernofsson and associates24 reported that TF
Figure 3. Plasma levels of fibrinogen preoperatively and up to the 60th postoperative day. Small open circles
represent observed values, and large filled circles represent fitted values from the statistical model.
Figure 4. Plasma levels of XDP preoperatively and up to the 60th postoperative day. Small open circles represent
observed values, and large filled circles represent fitted values from the statistical model.
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expression was not changed at the end of CPB, whereas a
significant increase of TF was recorded 20 hours after the
operation. Interestingly, the same authors documented such
an increase both in unstimulated monocytes and in mono-
cytes exposed to LPS. These data allowed the conclusion
that TF expression in circulating monocytes is upregulated
the day after heart operation. Our results extend this obser-
vation and suggest that relatively increased levels of TF
activity in the systemic circulation might persist longer after
the operation, thus addressing a role of TF as a generator of
thrombin not only during and immediately after the inter-
vention but also in a more prolonged follow-up period.
Previous data by Nieuwland and coworkers25 showed the
presence of higher levels of procoagulant cell-derived mi-
croparticles in pericardial blood from patients undergoing
CPB with respect to systemic circulation. The finding about
an increased procoagulant profile of the blood collected
from the pericardial cavity respective to systemic circula-
tion was also confirmed by a more recent study.26 These
results, however, have been obtained either after the release
of the aortic clamp (from 5-10 minutes) or in a time frame
from 15 to 60 minutes on bypass, respectively. In the latter
condition, plasma TF from the systemic circulation was not
increased, thus reflecting a different behavior between cells
involved in the surgical damage and those from peripheral
blood26 under the profile of time requested for TF to be
exposed.
The observed upregulation of TF activity is strictly par-
alleled by activation of coagulation detected as an increase
of prothrombin fragment F1.2 levels used as a marker for
thrombin generation. The coagulopathy profile persists for
longer time periods from the intervention, as documented
by fibrinogen and TAT levels that are still increased 15 and
30 days postoperatively, respectively.
One limitation of this study is that no control group of
patients undergoing another type of operation was studied;
for this reason, this study cannot clearly address whether
changes in coagulation-fibrinolytic variables are specific for
cardiac surgery with CPB or common to all surgical proce-
dures and wound healing. This issue is rather controversial.
Indeed, it has been previously shown that coagulation and
fibrinolytic variables are altered after some types of skeletal
surgery27 and, in contrast, that a major activation of coag-
ulation and fibrinolysis occurs after cardiac surgery per-
formed with CPB but not after general thoracic surgery.7
Regardless of the different conclusions, it should be pointed
out that the observation period considered in the above
studies is limited to the first 24 to 48 hours after the
operation. No information, however, is available about the
behavior of the considered variables for longer periods of
time.
At present, current indication for the prevention of car-
diovascular events in patients undergoing CPB is to pre-
scribe aspirin.18 Our observation of a persistent activation of
coagulation 2 months after CPB raises the question of
whether antithrombotic therapy should be reconsidered.
However, this question needs to be answered on the basis of
the results emerging from appropriately designed clinical
trials.
Figure 5. TF activity by PBMLs (expressed as ratio of LPS-stimulated/LPS-unstimulated cells) preoperatively and
up to the eighth postoperative day. Small open circles represent observed values, and large filled circles represent
fitted values from the statistical model.
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